5 Papers
1 Citations
Le Zhang is an academic researcher from Tianjin Medical University Cancer Institute and Hospital. The author has contributed to research in topics: Diffuse large B-cell lymphoma & International Prognostic Index. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia
Bing Xia,Chen Tian,Shanqi Guo,Le Zhang,Dandan Zhao,Fulian Qu,Weipeng Zhao,Yafei Wang,Xiaoxiong Wu,Wanming Da,Sheng Wei,Yizhuo Zhang +11 more
TL;DR: It is reported that mesenchymal stromal cells (MSC) are essential component of bone marrow microenvironment which affects the survival of AML cells and c-Myc is a potential therapeutic target for overcoming drug resistance in AML.
81
Overexpression of DNA methyltransferase 1 as a negative independent prognostic factor in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab.
TL;DR: DNMT1 was identified to be an independent prognostic factor for predicting the survival and progression-free survival of patients with PGI-DLBCL; this suggests that it could be used as a marker to indicate the prognosis of P GI- DLBCL.
Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma
Bing Xia,Le Zhang,Shan Qi Guo,Xiaowu Li,Fu Lian Qu,Haifeng Zhao,Lian Yu Zhang,Baocun Sun,James You,Yi Zhuo Zhang +9 more
TL;DR: MyC+/BCL-2+ patients have worse chemotherapy response and poorer prognosis than patients who only express one of the two proteins, suggesting that assessment of MYC and BCL-2 expression by immunohistochemistry has clinical significance in predicting clinical outcomes of PGI-DLBCL patients.
17
Downregulated expression of Dicer1 predicts inferior survival in primary gastrointestinal diffuse large B-cell lymphoma treated with CHOP-like regimen and rituximab
TL;DR: Dicer1, an independent prognostic factor for predicting shortened survival of patients with PGI-DLBCL, can be used as a biomarker to guide the prognosis.
4
Coexpression of MYC and BCL-2 Predicts Inferior Survival in Pgi-DLBCL Treated with CHOP-like Regimen/Rituximab
Le Zhang,Bing Xia,Shanqi Guo,Xiaowu Li,Fulian Qu,Haifeng Zhao,Lianyu Zhang,Baocun Sun,Liang Zhang,Yizhuo Zhang +9 more
TL;DR: Assessment of MYC and BCL-2 expression by immunohistochemistry has clinical significance in predicting prognosis of PGI-DLBCL patients, suggesting that MYC+/BCL-2+ patients have poorer chemotherapy response and poorer prognosis than patients who only express one of the two proteins.
1